RxDoctor Payments Data

Fernando Sorto, DO

Pulmonary Disease · Riverside, CANPI 1063705788

Payments from drug & device makers

$1,210in general payments, 2019–2025

Across 54 payments — averaging $22.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$191
  • Sanofi$142
  • GSK$127
  • United Therapeutics Corporation$124
  • Grifols USA, LLC$91
  • Insmed, Inc.$78
  • plus $457 from 13 others

What the payments were for

  • Food & beverage$1,210100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,210 in reported general payments places this provider in the 45th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$193,138
Medicare patients
380
Services billed
1,339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate23$293,668
Orenitram ErTreprostinil Diolamine22$154,905
NucalaMepolizumab14$47,731
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$29,872
Breo ElliptaFluticasone/Vilanterol74$29,555
Breztri AerosphereBudesonide/Glycopyr/Formoterol47$28,688
Spiriva RespimatTiotropium Bromide30$15,277
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$12,966
EliquisApixaban15$9,062
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate23$5,183
AirsupraAlbuterol Sulfate/Budesonide11$4,868
Fluticasone-VilanterolFluticasone/Vilanterol13$3,914
BreynaBudesonide/Formoterol Fumarate19$3,374
SymbicortBudesonide/Formoterol Fumarate13$2,908
Albuterol Sulfate HfaAlbuterol Sulfate69$1,763

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat$191$308,94453 claims
GSKNucala, Trelegy Ellipta, Breo Ellipta, Anoro Ellipta$127$120,124153 claims
AstraZenecaBreztri Aerosphere, Airsupra, Symbicort$29$36,46571 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,261 pulmonary disease providers in California.

Other pulmonary disease in Riverside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →